Chronic Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic cough markets reached a value of US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.
The chronic cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic cough refers to a respiratory tract illness in which cough lasts for an extended period of eight weeks or sometimes much longer. The condition develops in the upper airway of the respiratory system, causing sleep interruption and feelings of fatigue. The common symptoms of this disease include a runny or stuffy nose, sore throat, hoarseness, shortness of breath, wheezing, heartburn or a sour taste in the mouth, frequent throat clearing, etc. Individuals suffering from a chronic cough may also experience postnasal drip, persistent chest pain, coughing up blood, difficulty concentrating at work or school, fractured ribs, headache, and dizziness. Diagnosing this ailment is typically done by evaluating the patient’s clinical features, medical history, and physical examination. The healthcare provider may perform imaging tests, such as chest X-rays and computerized tomography (CT) scans, to detect the lung condition. Additionally, bronchoscopy or rhinoscopy can be used to visualize abnormalities in the nasal passageways, sinuses, and upper airways.
The increasing prevalence of respiratory infections due to high levels of air pollution, chain-smoking, prolonged exposure to dust and chemical fumes, etc., is primarily driving the chronic cough market. Additionally, the rising incidences of several disease-associated risk factors, including asthma, gastroesophageal reflux disease, chronic bronchitis, coronavirus infection, etc., are also bolstering the market growth. Besides this, the escalating usage of the upper endoscopy procedure, which involves the application of a flexible, lighted instrument to monitor the esophagus, stomach, and small intestine and provide disease diagnosis, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, bronchodilators, corticosteroids, decongestants, etc., to treat chronic cough by reducing inflammation and opening the airways is acting as another significant growth-inducing factor. In line with this, the growing popularity of over-the-counter cough suppressants, since they can help unclog a stuffy nose by clearing the mucus from the airway, is also augmenting the market growth. Additionally, the emerging application of laparoscopic antireflux surgery (LARS), that primarily aims to reduce acid reflux incidences and impart long-term symptom relief, is positively influencing the market. Furthermore, the rising focus on the development of innovative digital technology to monitor chronic cough conditions, which would aid patients in getting access to the right treatment, is expected to drive the chronic cough market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic cough market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic cough market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic cough market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic cough marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic cough market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic cough market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic cough market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic cough across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic cough by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic cough by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic cough across the seven major markets?
What is the size of the chronic cough patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic cough?
What will be the growth rate of patients across the seven major markets?
Chronic Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic cough drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic cough market?
What are the key regulatory events related to the chronic cough market?
What is the structure of clinical trial landscape by status related to the chronic cough market?
What is the structure of clinical trial landscape by phase related to the chronic cough market?
What is the structure of clinical trial landscape by route of administration related to the chronic cough market?
The chronic cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic cough refers to a respiratory tract illness in which cough lasts for an extended period of eight weeks or sometimes much longer. The condition develops in the upper airway of the respiratory system, causing sleep interruption and feelings of fatigue. The common symptoms of this disease include a runny or stuffy nose, sore throat, hoarseness, shortness of breath, wheezing, heartburn or a sour taste in the mouth, frequent throat clearing, etc. Individuals suffering from a chronic cough may also experience postnasal drip, persistent chest pain, coughing up blood, difficulty concentrating at work or school, fractured ribs, headache, and dizziness. Diagnosing this ailment is typically done by evaluating the patient’s clinical features, medical history, and physical examination. The healthcare provider may perform imaging tests, such as chest X-rays and computerized tomography (CT) scans, to detect the lung condition. Additionally, bronchoscopy or rhinoscopy can be used to visualize abnormalities in the nasal passageways, sinuses, and upper airways.
The increasing prevalence of respiratory infections due to high levels of air pollution, chain-smoking, prolonged exposure to dust and chemical fumes, etc., is primarily driving the chronic cough market. Additionally, the rising incidences of several disease-associated risk factors, including asthma, gastroesophageal reflux disease, chronic bronchitis, coronavirus infection, etc., are also bolstering the market growth. Besides this, the escalating usage of the upper endoscopy procedure, which involves the application of a flexible, lighted instrument to monitor the esophagus, stomach, and small intestine and provide disease diagnosis, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, bronchodilators, corticosteroids, decongestants, etc., to treat chronic cough by reducing inflammation and opening the airways is acting as another significant growth-inducing factor. In line with this, the growing popularity of over-the-counter cough suppressants, since they can help unclog a stuffy nose by clearing the mucus from the airway, is also augmenting the market growth. Additionally, the emerging application of laparoscopic antireflux surgery (LARS), that primarily aims to reduce acid reflux incidences and impart long-term symptom relief, is positively influencing the market. Furthermore, the rising focus on the development of innovative digital technology to monitor chronic cough conditions, which would aid patients in getting access to the right treatment, is expected to drive the chronic cough market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic cough market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic cough market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic cough market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic cough marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic cough market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic cough market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic cough market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic cough across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic cough by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic cough by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic cough across the seven major markets?
What is the size of the chronic cough patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic cough?
What will be the growth rate of patients across the seven major markets?
Chronic Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic cough drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic cough market?
What are the key regulatory events related to the chronic cough market?
What is the structure of clinical trial landscape by status related to the chronic cough market?
What is the structure of clinical trial landscape by phase related to the chronic cough market?
What is the structure of clinical trial landscape by route of administration related to the chronic cough market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC COUGH - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC COUGH - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC COUGH - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC COUGH - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC COUGH - UNMET NEEDS
10 CHRONIC COUGH - KEY ENDPOINTS OF TREATMENT
11 CHRONIC COUGH - MARKETED PRODUCTS
11.1 List of Chronic Cough Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC COUGH - PIPELINE DRUGS
12.1 List of Chronic Cough Pipeline Drugs Across the Top 7 Markets
12.1.1 S 600918 - Shionogi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AX-8 - Axalbion
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ADX-629 - Aldeyra Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Gefapixant - Merck & Co
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BAY1817080 - Bayer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC COUGH - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC COUGH – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC COUGH - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Cough - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Cough - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Cough - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Cough - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Cough - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Cough - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Cough - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Cough - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Cough - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Cough - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Cough - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Cough - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Cough - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Cough - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Cough - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Cough - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Cough - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Cough - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Cough - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Cough - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Cough - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Cough - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Cough - Access and Reimbursement Overview
16 CHRONIC COUGH - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC COUGH MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC COUGH MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC COUGH - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC COUGH - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC COUGH - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC COUGH - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC COUGH - UNMET NEEDS
10 CHRONIC COUGH - KEY ENDPOINTS OF TREATMENT
11 CHRONIC COUGH - MARKETED PRODUCTS
11.1 List of Chronic Cough Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC COUGH - PIPELINE DRUGS
12.1 List of Chronic Cough Pipeline Drugs Across the Top 7 Markets
12.1.1 S 600918 - Shionogi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AX-8 - Axalbion
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ADX-629 - Aldeyra Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Gefapixant - Merck & Co
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BAY1817080 - Bayer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC COUGH - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC COUGH – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC COUGH - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Cough - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Cough - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Cough - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Cough - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Cough - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Cough - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Cough - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Cough - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Cough - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Cough - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Cough - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Cough - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Cough - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Cough - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Cough - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Cough - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Cough - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Cough - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Cough - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Cough - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Cough - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Cough - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Cough - Access and Reimbursement Overview
16 CHRONIC COUGH - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC COUGH MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC COUGH MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
